Chronic condition

U.S. Chronic Pain Market and Competitive Landscape 2020 - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 3, 2020
Health, Pharmaceutical, Perception, Nociception, Acute pain, Chronic condition, Medical terminology, Pain, Chronic pain, Pain management

The "US Chronic Pain Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Chronic Pain Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive insights into Chronic Pain pipeline products, Chronic Pain epidemiology, Chronic Pain market valuations and forecast, Chronic Pain drugs sales and competitive landscape in the US.
  • Chronic Pain pipeline: Find out the products in clinical trials for the treatment of Chronic Pain by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Chronic Pain drugs: Identify key products marketed and prescribed for Chronic Pain in the US, including trade name, molecule name, and company
    Chronic Pain market valuations: Find out the market size for Chronic Pain drugs in 2019 in the US.
  • Find out how the market advanced from 2016 and forecast to 2025
    Chronic Pain drugs market share: Find out the market shares for key Chronic Pain drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Chronic Pain products

Poxel to Host Conference Call for First Half 2020 Financial Results on September 15, 2020

Retrieved on: 
Thursday, September 3, 2020
Biotechnology, Diabetes, Other Health, Health, Pharmaceutical, Sumitomo Group, Sumitomo Dainippon Pharma, Chronic condition, Companies, Economy of Japan

The management team will host a conference call on September 15, 2020 in English at 1:30 pm EDT (New York time) / 7:30 pm CEST (Paris time) to present the financial results and provide a corporate update.

Key Points: 
  • The management team will host a conference call on September 15, 2020 in English at 1:30 pm EDT (New York time) / 7:30 pm CEST (Paris time) to present the financial results and provide a corporate update.
  • To access the conference call, please use the dial-in numbers below according to your location.
  • Poxel has a strategic partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries.
  • Poxel also has additional earlier-stage programs from its AMPK activator and deuterated TZD platforms targeting chronic and rare metabolic diseases.

Medical Device Contract Manufacturing Market Size is Projected To Reach USD 92,511.21 Million by 2025 | Valuates Reports

Retrieved on: 
Thursday, September 3, 2020
Medical terminology, Medical device, Chronic condition, Medicine

In turn, this is expected to increase the growth of the medical device contract manufacturing market size.

Key Points: 
  • In turn, this is expected to increase the growth of the medical device contract manufacturing market size.
  • The medical device contract manufacturing market size is driven by the need to minimize production costs and improve time-to-market effective and regulatory compliant medical devices.
  • Furthermore, the medical device contract manufacturing market size is driven by the rising prevalence of non-invasive surgical procedures.
  • The growing geriatric population and the resulting rise in the incidence and prevalence of chronic diseases are also driving the growth of the Medical Device Contract Manufacturing market size.

Medical Device Contract Manufacturing Market Size is Projected To Reach USD 92,511.21 Million by 2025 | Valuates Reports

Retrieved on: 
Thursday, September 3, 2020
Medical terminology, Medical device, Chronic condition, Medicine

In turn, this is expected to increase the growth of the medical device contract manufacturing market size.

Key Points: 
  • In turn, this is expected to increase the growth of the medical device contract manufacturing market size.
  • The medical device contract manufacturing market size is driven by the need to minimize production costs and improve time-to-market effective and regulatory compliant medical devices.
  • Furthermore, the medical device contract manufacturing market size is driven by the rising prevalence of non-invasive surgical procedures.
  • The growing geriatric population and the resulting rise in the incidence and prevalence of chronic diseases are also driving the growth of the Medical Device Contract Manufacturing market size.

Gala Therapeutics Announces Publication of Multicenter Study of the Minimally Invasive RheOx™ System in Patients with Chronic Bronchitis

Retrieved on: 
Thursday, September 3, 2020
Chronic lower respiratory diseases, Pulmonology, Organ systems, Respiratory system, Bronchitis, RTT, Respiratory disease, Bronchus, COPD: Journal of Chronic Obstructive Pulmonary Disease, Chronic obstructive pulmonary disease, Lung, Chronic condition

MENLO PARK, Calif., Sept. 3, 2020 /PRNewswire/ --Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, today announced the publication of the results from its initial study evaluating the RheOx Bronchial Rheoplasty System for chronic bronchitis.

Key Points: 
  • MENLO PARK, Calif., Sept. 3, 2020 /PRNewswire/ --Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, today announced the publication of the results from its initial study evaluating the RheOx Bronchial Rheoplasty System for chronic bronchitis.
  • The prospective multi-center study evaluated the use of RheOx in patients with moderate to severe chronic bronchitis, a phenotype of Chronic Obstructive Pulmonary Disease(COPD), which affects more than 9 million Americans.
  • "There is a significant unmet need for a therapy that can improve the quality of life for chronic bronchitis patients," said Jonathan Waldstreicher, MD, CEO of Gala Therapeutics.
  • RheOx is a bronchoscopic system designed to reduce mucus-producing cells in patients with Chronic Bronchitis.

Mayo Clinic expands collaboration with Viome to include heart disease, obesity and insomnia

Retrieved on: 
Thursday, September 3, 2020
Medicine, Medical terminology, Articles, Health, Mayo Clinic, Chronic condition, Disease, Obesity, Autoimmunity

SEATTLE, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Viome, a research-driven precision healthcare company, today announced that it has expanded its collaboration with Mayo Clinic beyond the initial focus of obesity and insomnia.

Key Points: 
  • SEATTLE, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Viome, a research-driven precision healthcare company, today announced that it has expanded its collaboration with Mayo Clinic beyond the initial focus of obesity and insomnia.
  • Mayo Clinic and Dr. Somers have a financial interest in the technology referenced in this news release.
  • Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
  • The ultimate goal is to prevent and reverse chronic diseases such as depression, obesity, heart diseases, autoimmune diseases, and diabetes, and empower people to live healthier lives.

BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences

Retrieved on: 
Thursday, September 3, 2020
Health, Managed care, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Chronic cough, Cough, Chronic condition

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (BELLUS Health or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will participate in two upcoming virtual healthcare investor conferences.

Key Points: 
  • BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (BELLUS Health or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will participate in two upcoming virtual healthcare investor conferences.
  • Replays from the Baird and H.C. Wainwright events may be accessed on the Events and Presentations page under the Investors & News section of BELLUS Health's website at www.bellushealth.com .
  • BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders.
  • The Company's product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.

National Mental Health Non-Profit, One Mind, Awards $600,000 in Grants to Two "Rising Stars" in Neuroscience and Psychiatry, Greg Fonzo, UT Austin, and Kevin Beier, UC Irvine

Retrieved on: 
Tuesday, September 1, 2020
Psychiatry, Psychiatric diagnosis, Mind, Articles, Abnormal psychology, RTT, Neuroscience, Mental disorder, Psychiatric assessment, Chronic condition, Alzheimer's disease, Parkinson's disease

Now in its 16th year, the Rising Star Awards support early career researchers in their investigation into neuropsychiatric disorders.

Key Points: 
  • Now in its 16th year, the Rising Star Awards support early career researchers in their investigation into neuropsychiatric disorders.
  • The awards are designed to catalyze innovation in the field by awarding novel approaches along with fostering greater collaboration among research teams.
  • For more information about One Mind's Rising Star Awards, or to learn about the organization's many initiatives, visit www.OneMind.org .
  • The Inscopix platform and data will enable advances in conditions including Alzheimer's, Parkinson's, psychiatric disorders, chronic pain, and addiction.

Global Chronic Spontaneous Urticaria (CSU) Market 2017-2030 with Analysis on Emerging Drugs Dupilumab (Sanofi/Regeneron) and Ligelizumab (Novartis Pharmaceuticals)

Retrieved on: 
Tuesday, September 1, 2020
Organ systems, Hives, RTT, Type I hypersensitivity, Medical specialties, Medicine, Chronic condition, Rare diseases, Monoclonal antibodies, Physical urticaria

The disease epidemiology covered in the report provides historical as well as forecasted Chronic spontaneous urticaria (CSU) symptoms epidemiology segmented as the Total Prevalent cases of Chronic spontaneous urticaria (CSU), Gender-Specific cases of Chronic spontaneous urticaria (CSU), Age-Specific cases of Chronic spontaneous urticaria (CSU).

Key Points: 
  • The disease epidemiology covered in the report provides historical as well as forecasted Chronic spontaneous urticaria (CSU) symptoms epidemiology segmented as the Total Prevalent cases of Chronic spontaneous urticaria (CSU), Gender-Specific cases of Chronic spontaneous urticaria (CSU), Age-Specific cases of Chronic spontaneous urticaria (CSU).
  • The drug chapter segment of the Chronic spontaneous urticaria (CSU) report encloses the detailed analysis of Chronic spontaneous urticaria (CSU) marketed drugs and early stage (Phase-I, II, III) pipeline drugs.
  • The analysis covers Chronic spontaneous urticaria (CSU) market uptake by drugs; patient uptake by therapies; and sales of each drug.
  • Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chronic spontaneous urticaria (CSU) market trend.

Pain Awareness Month campaign highlights gaps in pain care

Retrieved on: 
Monday, August 31, 2020
Perception, Acute pain, Nociception, Palliative care, Pain, Chronic pain, Chronic condition

In particular, 72% of respondents were not able to afford multidisciplinary care options, the type of care widely viewed as best practice.

Key Points: 
  • In particular, 72% of respondents were not able to afford multidisciplinary care options, the type of care widely viewed as best practice.
  • Released this week in honor of September as Pain Awareness Month, the survey is part of a national campaign to call attention to challenges in accessing pain management.
  • Pain Foundation, a nonprofit organization for the 50 million Americans with chronic pain, and Sunbeam, a maker of electric appliances, including heat therapy products.
  • A social media campaign, #MyPainPlan, highlighting best practices in pain care, and drawing attention to the barriers patients face in accessing it.